| DrugRepV_0605 | Amlodipine | Cardiovascular agents | Hypertension | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (61 %) | Approved | 23577127 |
| DrugRepV_0606 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (51 %) | Approved | 23577127 |
| DrugRepV_0607 | Biperiden | Nervous System | Parkinson disease | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (27 %) | Approved | 23577127 |
| DrugRepV_0608 | Carprofen | Anti-inflammatory | Joint pain | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Withdrawn | 23577127 |
| DrugRepV_0609 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (34 %) | Approved | 23577127 |
| DrugRepV_0610 | Dexbrompheniramine | Respiratory System | Allergies | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (74 %) | Approved | 23577127 |
| DrugRepV_0611 | Dibucaine | Nervous System | Anesthesia | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (49 %) | Approved | 23577127 |
| DrugRepV_0612 | Diphenoxylate | Alimentary Tract and Metabolism | Diarrhea | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (83 %) | Approved | 23577127 |
| DrugRepV_0613 | Diphenylpyraline | Respiratory System | Allergies | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (22 %) | Approved | 23577127 |
| DrugRepV_0614 | Dipivefrin | Sensory Organ | Glaucoma | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (90 %) | Approved | 23577127 |
| DrugRepV_0615 | Dirithromycin | Antiinfectives For Systemic Use | Bacterial infections | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | No significant effect (0 %) | Approved | 23577127 |
| DrugRepV_0616 | Erythromycin | Antiinfectives For Systemic Use | Bacterial infections | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (60 %) | Approved | 23577127 |
| DrugRepV_0617 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0618 | Fluoxetine | Nervous System | Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (76 %) | Approved, Vet approved | 23577127 |
| DrugRepV_0619 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (33 %) | Approved | 23577127 |
| DrugRepV_0620 | Levopropoxyphene | Respiratory-Tract-agents | Cough and associated respiratory tract disorders | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (79 %) | Withdrawn | 23577127 |
| DrugRepV_0621 | Mycophenolate Mofetil | Immunosuppressant | Organ rejection (immunosuppressants) | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (69 %) | Approved, Investigational | 23577127 |
| DrugRepV_0622 | Oxyphencyclimine | Alimentary Tract and Metabolism | Peptic ulcers | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (28 %) | Approved | 23577127 |
| DrugRepV_0623 | Paroxetine | Nervous System | Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD) | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | No significant effect (6 %) | Approved, Investigational | 23577127 |
| DrugRepV_0624 | Penbutolol | Cardiovascular agents | Arterial hypertension | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (67 %) | Approved, Investigational | 23577127 |
| DrugRepV_0625 | Prochlorperazine | Nervous System | Nausea | Vomiting | Schizophrenia | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (70 %) | Approved | 23577127 |
| DrugRepV_0626 | Protriptyline | Nervous System | Depressive disorder | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (28 %) | Approved | 23577127 |
| DrugRepV_0627 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (76 %) | Approved, Investigational | 23577127 |
| DrugRepV_0628 | Trihexyphenidyl | Nervous System | Parkinson Disease | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (52 %) | Approved | 23577127 |
| DrugRepV_0644 | Amlodipine | Cardiovascular agents | Hypertension | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (93 %) | Approved | 23577127 |
| DrugRepV_0645 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (97 %) | Approved | 23577127 |
| DrugRepV_0646 | Biperiden | Nervous System | Parkinson disease | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (89 %) | Approved | 23577127 |
| DrugRepV_0647 | Carprofen | Anti-inflammatory | Joint pain | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (88 %) | Approved, Withdrawn | 23577127 |
| DrugRepV_0648 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (97 %) | Approved | 23577127 |
| DrugRepV_0649 | Dexbrompheniramine | Respiratory System | Allergies | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (80 %) | Approved | 23577127 |
| DrugRepV_0650 | Dibucaine | Nervous System | Anesthesia | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (93 %) | Approved | 23577127 |
| DrugRepV_0651 | Diphenoxylate | Alimentary Tract and Metabolism | Diarrhea | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (95 %) | Approved | 23577127 |
| DrugRepV_0652 | Diphenylpyraline | Respiratory System | Allergies | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (85 %) | Approved | 23577127 |
| DrugRepV_0653 | Dipivefrin | Sensory Organ | Glaucoma | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (90 %) | Approved | 23577127 |
| DrugRepV_0654 | Dirithromycin | Antiinfectives For Systemic Use | Bacterial infections | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (91 %) | Approved | 23577127 |
| DrugRepV_0655 | Erythromycin | Antiinfectives For Systemic Use | Bacterial infections | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (98 %) | Approved | 23577127 |
| DrugRepV_0656 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (98 %) | Approved | 23577127 |
| DrugRepV_0657 | Fluoxetine | Nervous System | Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (98 %) | Approved, Vet approved | 23577127 |
| DrugRepV_0658 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (97 %) | Approved | 23577127 |
| DrugRepV_0659 | Levopropoxyphene | Respiratory-Tract-agents | Cough and associated respiratory tract disorders | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (89 %) | Withdrawn | 23577127 |
| DrugRepV_0660 | Mycophenolate Mofetil | Immunosuppressant | Organ rejection (immunosuppressants) | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (81 %) | Approved, Investigational | 23577127 |
| DrugRepV_0661 | Oxyphencyclimine | Alimentary Tract and Metabolism | Peptic ulcers | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (89 %) | Approved | 23577127 |
| DrugRepV_0662 | Paroxetine | Nervous System | Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD) | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (89 %) | Approved, Investigational | 23577127 |
| DrugRepV_0663 | Penbutolol | Cardiovascular agents | Arterial hypertension | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (81 %) | Approved, Investigational | 23577127 |
| DrugRepV_0664 | Prochlorperazine | Nervous System | Nausea | Vomiting | Schizophrenia | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (93 %) | Approved | 23577127 |
| DrugRepV_0665 | Protriptyline | Nervous System | Depressive disorder | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (80 %) | Approved | 23577127 |
| DrugRepV_0666 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (96 %) | Approved, Investigational | 23577127 |
| DrugRepV_0667 | Trihexyphenidyl | Nervous System | Parkinson Disease | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (91 %) | Approved | 23577127 |
| DrugRepV_0668 | Amlodipine | Cardiovascular agents | Hypertension | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (93 %) | Approved | 23577127 |
| DrugRepV_0669 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (99 %) | Approved | 23577127 |
| DrugRepV_0670 | Biperiden | Nervous System | Parkinson disease | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (98 %) | Approved | 23577127 |
| DrugRepV_0671 | Carprofen | Anti-inflammatory | Joint pain | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (94 %) | Approved, Withdrawn | 23577127 |
| DrugRepV_0672 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (97 %) | Approved | 23577127 |
| DrugRepV_0673 | Dexbrompheniramine | Respiratory System | Allergies | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (85 %) | Approved | 23577127 |
| DrugRepV_0674 | Dibucaine | Nervous System | Anesthesia | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (99 %) | Approved | 23577127 |
| DrugRepV_0675 | Diphenoxylate | Alimentary Tract and Metabolism | Diarrhea | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (96 %) | Approved | 23577127 |
| DrugRepV_0676 | Diphenylpyraline | Respiratory System | Allergies | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (96 %) | Approved | 23577127 |
| DrugRepV_0677 | Dipivefrin | Sensory Organ | Glaucoma | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (94 %) | Approved | 23577127 |
| DrugRepV_0678 | Dirithromycin | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (99 %) | Approved | 23577127 |
| DrugRepV_0679 | Erythromycin | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (96 %) | Approved | 23577127 |
| DrugRepV_0680 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (93 %) | Approved | 23577127 |
| DrugRepV_0681 | Fluoxetine | Nervous System | Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (96 %) | Approved, Vet approved | 23577127 |
| DrugRepV_0682 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (99 %) | Approved | 23577127 |
| DrugRepV_0683 | Levopropoxyphene | Respiratory-Tract-agents | Cough and associated respiratory tract disorders | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (98 %) | Withdrawn | 23577127 |
| DrugRepV_0684 | Mycophenolate Mofetil | Immunosuppressant | Organ rejection (immunosuppressants) | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (91 %) | Approved, Investigational | 23577127 |
| DrugRepV_0685 | Oxyphencyclimine | Alimentary Tract and Metabolism | Peptic ulcers | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (95 %) | Approved | 23577127 |
| DrugRepV_0686 | Paroxetine | Nervous System | Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD) | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (98 %) | Approved, Investigational | 23577127 |
| DrugRepV_0687 | Penbutolol | Cardiovascular agents | Arterial hypertension | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (98 %) | Approved, Investigational | 23577127 |
| DrugRepV_0688 | Prochlorperazine | Nervous System | Nausea | Vomiting | Schizophrenia | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (95 %) | Approved | 23577127 |
| DrugRepV_0689 | Protriptyline | Nervous System | Depressive disorder | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (83 %) | Approved | 23577127 |
| DrugRepV_0690 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (97 %) | Approved, Investigational | 23577127 |
| DrugRepV_0691 | Trihexyphenidyl | Nervous System | Parkinson Disease | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (97 %) | Approved | 23577127 |
| DrugRepV_0709 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0711 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0712 | Aminoquinoline-13 | NA | Malaria | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | NA | 23577127 |
| DrugRepV_0717 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0718 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0719 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 23577127 |
| DrugRepV_0720 | Aminoquinoline-13 | NA | Malaria | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (50 %) | NA | 23577127 |
| DrugRepV_1562 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (93 %) | Approved, Investigational | 26217313 |
| DrugRepV_1563 | Masitinib | Antineoplastic and Immunomodulating Agents | Mast cell tumors in dogs | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (84 %) | Investigational, Vet approved | 26217313 |
| DrugRepV_1564 | Desmethyl Erlotinib | NA | Cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (65 %) | Approved, Investigational | 26217313 |
| DrugRepV_1565 | Pazopanib Hydrochloride | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (61 %) | Approved | 26217313 |
| DrugRepV_1566 | Paclitaxel | Antineoplastic and Immunomodulating Agents | Kaposi's sarcoma | Lung cancer | Ovarian cancer | Breast cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (78 %) | Approved | 26217313 |
| DrugRepV_1567 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (61 %) | Approved | 26217313 |
| DrugRepV_1568 | Docetaxel | Antineoplastic and Immunomodulating Agents | Cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (45 %) | Approved | 26217313 |
| DrugRepV_1569 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (72 %) | Approved, Investigational | 26217313 |
| DrugRepV_1570 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (68 %) | Approved | 26217313 |
| DrugRepV_1571 | Fulvestrant | Antineoplastic and Immunomodulating Agents | Breast cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (43 %) | Approved, Investigational | 26217313 |
| DrugRepV_1572 | Fenbendazole | Antiparasitic products, Insectisides and Repellents | Helminthiasis | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (81 %) | Vet approved | 26217313 |
| DrugRepV_1573 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (57 %) | Approved, Investigational, Vet approved | 26217313 |
| DrugRepV_1574 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (86 %) | Approved | 26217313 |
| DrugRepV_1575 | Teniposide | Antineoplastic and Immunomodulating Agents | Acute lymphoblastic leukaemia | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (57 %) | Approved | 26217313 |
| DrugRepV_1576 | Itraconazole | Antiinfectives For Systemic Use | Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis) | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (74 %) | Approved, Investigational | 26217313 |
| DrugRepV_1577 | Clotrimazole | Dermatologicals | Fungal infections | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (33 %) | Approved | 26217313 |
| DrugRepV_1578 | Clemastine Fumarate | Respiratory System | Allergic rhinitis | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (63 %) | Approved | 26217313 |
| DrugRepV_1579 | Manidipine Dihydrochloride | Cardiovascular agents | Hypertension | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (63 %) | Approved, Investigational | 26217313 |
| DrugRepV_1580 | Floxuridine | Anticancer | Gastrointestinal adenocarcinomas | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (45 %) | Approved | 26217313 |
| DrugRepV_1581 | Maprotiline Hydrochloride | Nervous System | Bipolar depression | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (41 %) | Approved, Investigational | 26217313 |
| DrugRepV_1582 | Quetiapine Fumarate | Nervous System | Schizophrenia | Bipolar disorder | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (41 %) | Approved | 26217313 |
| DrugRepV_1586 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 26217313 |
| DrugRepV_1589 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (90 %) | Approved, Investigational | 26217313 |
| DrugRepV_1590 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Luciferase reporter assay | Decrease (90 %) | Approved, Investigational | 26217313 |
| DrugRepV_2069 | Lacidipine | Cardiovascular agents | Hypertension | Lassa virus | LASVpv | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 29899092 |
| DrugRepV_2070 | Phenothrin | NA | NA | Lassa virus | LASVpv | NA | Luciferase reporter assay | Decrease (50 %) | Experimental | 29899092 |
| DrugRepV_2071 | Diphenhydramine | Dermatologicals and Respiratory System | Vertigo/Meniere's disease, nausea and vomiting, motion sickness and insect bite | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2072 | Chlorcyclizine | Respiratory System | Allergic rhinitis | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2073 | Diphenhydramine | Dermatologicals and Respiratory System | Vertigo/Meniere's disease, nausea and vomiting, motion sickness and insect bite | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2074 | Chlorcyclizine | Respiratory System | Allergic rhinitis | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2075 | Cetirizine | Respiratory System | Allergic rhinitis | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved | 29981374 |
| DrugRepV_2076 | Cetirizine | Respiratory System | Allergic rhinitis | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved | 29981374 |
| DrugRepV_2077 | Fexofenadine | Respiratory System | Allergic rhinitis | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved, Investigational | 29981374 |
| DrugRepV_2078 | Fexofenadine | Respiratory System | Allergic rhinitis | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved, Investigational | 29981374 |
| DrugRepV_2079 | Tiotidine | NA | NA | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | No significant decrease (50 %) | NA | 29981374 |
| DrugRepV_2080 | Tiotidine | NA | NA | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | No significant decrease (50 %) | NA | 29981374 |
| DrugRepV_2081 | Impentamine | NA | NA | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | No significant decrease (50 %) | NA | 29981374 |
| DrugRepV_2082 | Impentamine | NA | NA | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | No significant decrease (50 %) | NA | 29981374 |
| DrugRepV_2083 | JNJ7777120 | Anti-inflammatory | Pruritus (itching) | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | NA | 29981374 |
| DrugRepV_2084 | JNJ7777120 | Anti-inflammatory | Pruritus (itching) | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | NA | 29981374 |
| DrugRepV_2085 | Nordiphenhydramine | NA | NA | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | NA | 29981374 |
| DrugRepV_2086 | Nordiphenhydramine | NA | NA | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | NA | 29981374 |
| DrugRepV_2087 | Orphenadrine | Nervous System | Parkinson's disease | Muscle spasm | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2088 | Orphenadrine | Nervous System | Parkinson's disease | Muscle spasm | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2089 | Chlorphenoxamine | Respiratory System | Parkinson's | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Withdrawn | 29981374 |
| DrugRepV_2090 | Chlorphenoxamine | Respiratory System | Parkinson's | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Withdrawn | 29981374 |
| DrugRepV_2091 | Carbinoxamine | Respiratory System | Allergic rhinitis | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2092 | Carbinoxamine | Respiratory System | Allergic rhinitis | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2093 | Doxylamine | Respiratory System | Allergies and an antitussive, antiemetic, and hypnotic | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2094 | Doxylamine | Respiratory System | Allergies and an antitussive, antiemetic, and hypnotic | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved | 29981374 |
| DrugRepV_2095 | Hydroxyzine | Nervous System | Anxiety | Tension | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2096 | Hydroxyzine | Nervous System | Anxiety | Tension | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2097 | Cyclizine | Respiratory System | Nausea, vomiting, and dizziness | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2098 | Cyclizine | Respiratory System | Nausea, vomiting, and dizziness | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2099 | Buclizine | Respiratory System | Nausea, vomiting, and dizziness | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2100 | Buclizine | Respiratory System | Nausea, vomiting, and dizziness | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2101 | Meclizine | Respiratory System | Nausea | Vomiting | Motion sickness | Vertigo | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2102 | Meclizine | Respiratory System | Nausea | Vomiting | Motion sickness | Vertigo | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_3038 | Berberine | NA | Parasitic and fungal infection | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 26752081 |
| DrugRepV_3039 | Abamectin | NA | Helmintic infection | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Terminated | 26752081 |
| DrugRepV_3040 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational, Vet approved | 26752081 |
| DrugRepV_3041 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Investigational | 26752081 |
| DrugRepV_3042 | Bromocriptine | Nervous System | Parkinson disease | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 26752081 |
| DrugRepV_3043 | Berberine | NA | Parasitic and fungal infection | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 26752081 |
| DrugRepV_3044 | Abamectin | NA | Helmintic infection | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Terminated | 26752081 |
| DrugRepV_3045 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational, Vet approved | 26752081 |
| DrugRepV_3046 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Investigational | 26752081 |
| DrugRepV_3047 | Bromocriptine | Nervous System | Parkinson disease | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 26752081 |
| DrugRepV_3048 | Abamectin | NA | Helmintic infection | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (100 %) | Terminated | 26752081 |
| DrugRepV_3049 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (100 %) | Approved, Investigational, Vet approved | 26752081 |
| DrugRepV_3050 | Berberine | NA | Parasitic and fungal infection | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (87 %) | Approved | 26752081 |
| DrugRepV_3051 | Amphotericin B | Antiinfectives For Systemic Use | Fungal infection | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (77 %) | Approved | 26752081 |
| DrugRepV_3052 | Cerivastatin | Cardiovascular agents | Rhabdomyolysis | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (70 %) | Approved | 26752081 |
| DrugRepV_3053 | Bromocriptine | Nervous System | Parkinson disease | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (65 %) | Approved | 26752081 |
| DrugRepV_3054 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (40 %) | Investigational | 26752081 |
| DrugRepV_3055 | Clotrimazole | Dermatologicals | Fungal infection | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (30 %) | Approved | 26752081 |
| DrugRepV_3056 | Bifonazole | Dermatologicals | Fungal infection | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (22 %) | Approved | 26752081 |
| DrugRepV_3057 | Miconazole | Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System; Sex Hormones; Antiinfective | Fungal infections (Tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment o | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (22 %) | Approved, Investigational, Vet approved | 26752081 |
| DrugRepV_3058 | Atovaquone | Antiparasitic products, Insectisides and Repellents | Malaria | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (20 %) | Approved | 26752081 |
| DrugRepV_3059 | Triclabendazole | Antiparasitic products, Insectisides and Repellents | Fascioliasis (Parasitic infection) | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (20 %) | Approved, Investigational | 26752081 |
| DrugRepV_3060 | Efavirenz | Antiinfectives For Systemic Use | Acquired immuno deficiency syndrome | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (10 %) | Approved | 26752081 |
| DrugRepV_3571 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3572 | Trifluoperazine | Nervous System | Schizophrenia and other psychotic disorders | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3573 | Clomipramine | Nervous System | Depression, schizophrenia, Tourette disorder | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3574 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3575 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3576 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3577 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3578 | AY9944 | NA | NA | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3579 | Paroxetine | Nervous System | Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD) | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3580 | Thioridazine | Nervous System | Schizophrenia | Anxiety disorder | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Withdrawn | 30149038 |
| DrugRepV_3581 | GBR-12783 | NA | Psychosis | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3582 | Tabimorelin | NA | NA | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3583 | Asenapine | Nervous System | Psychosis | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3584 | Camylofine | NA | NA | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3585 | Bisacodyl | Alimentary Tract and Metabolism | Colon cleansing | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3586 | Bisacodyl | Alimentary Tract and Metabolism | Colon cleansing | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3587 | ML9 | NA | NA | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3588 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3589 | Sertraline | Nervous System | Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3590 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3591 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Withdrawn | 30149038 |
| DrugRepV_3592 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3593 | Iminodyn 17 | NA | NA | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3594 | Nobiletin | NA | NA | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3595 | Ferroquine | Antimalarial | Malaria | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3596 | N-Acetyl-L-leucyl- L- leucyl-L- methional | NA | NA | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3597 | Calpeptin | NA | NA | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | NA | 30149038 |
| DrugRepV_3665 | 2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine | NA | NA | Marburg virus | Lake Victoria | NA | Luciferase reporter assay | Decrease (90 %) | NA | 21270170 |
| DrugRepV_3666 | 2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine | NA | NA | Marburg virus | Lake Victoria | NA | Luciferase reporter assay | Decrease (50 %) | NA | 21270170 |
| DrugRepV_3667 | 2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine | NA | NA | Marburg virus | Lake Victoria | NA | Luciferase reporter assay | Decrease (100 %) | NA | 21270170 |
| DrugRepV_3668 | 2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine | NA | NA | Marburg virus | Lake Victoria | NA | Luciferase reporter assay | Decrease (98 %) | NA | 21270170 |
| DrugRepV_3669 | 2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine | NA | NA | Lassa virus | NA | NA | Luciferase reporter assay | Decrease (40 %) | NA | 21270170 |
| DrugRepV_3670 | 2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine | NA | NA | Influenza virus | Goose/Qinghai/59/05 |  | Luciferase reporter assay | Decrease (15 %) | NA | 21270170 |
| DrugRepV_5711 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Dengue virus | NA | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 29753658 |
| DrugRepV_5712 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | NA | | Luciferase reporter assay | Decrease (50 %) | Approved | 29753658 |
| DrugRepV_5748 | Manidipine | Cardiovascular agents | Hypertension | Dengue virus | DENV-2 replicon | | Luciferase reporter assay | Decrease (75 %) | Approved, Investigational | 28814523 |
| DrugRepV_5749 | Cilnidipine | Cardiovascular agents | Hypertension | Dengue virus | DENV-2 replicon | | Luciferase reporter assay | Decrease (90 %) | Approved | 28814523 |
| DrugRepV_5750 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Dengue virus | DENV-2 replicon | | Luciferase reporter assay | Decrease (100 %) | Approved | 28814523 |
| DrugRepV_5751 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Dengue virus | DENV-2 replicon | | Luciferase reporter assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_5752 | Nelfinavir Mesylate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Dengue virus | DENV-2 replicon | | Luciferase reporter assay | No significant effect (0 %) | NA | 28814523 |
| DrugRepV_6002 | U18666A | NA | NA | Dengue virus | Replicon systen | | Luciferase reporter assay | Decrease (50 %) | NA | 22146564 |
| DrugRepV_6003 | U18666A | NA | NA | Dengue virus | Replicon systen | | Luciferase reporter assay | Decrease (50 %) | NA | 22146564 |
| DrugRepV_6032 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea C | | Luciferase reporter assay | Decrease (1 Log) | Investigational | 23616652 |
| DrugRepV_6033 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Luciferase reporter assay | No significant effect (0.4 Log) | Approved | 23616652 |
| DrugRepV_6481 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Human immunodeficiency virus | NL4-3 | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_6482 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Human immunodeficiency virus | NL4-3 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_6483 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Human immunodeficiency virus | HXB2 luciferase reporter virus | | Luciferase reporter assay | Decrease (60 %) | Approved | 26807966 |
| DrugRepV_6484 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Human immunodeficiency virus | JR-FL luciferase reporter virus | | Luciferase reporter assay | Decrease (90 %) | Approved | 26807966 |
| DrugRepV_6485 | Saracatinib | Anticancer | Osteosarcoma | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Human immunodeficiency virus | HXB2 luciferase reporter virus | | Luciferase reporter assay | Decrease (60 %) | Investigational | 26807966 |
| DrugRepV_6486 | Saracatinib | Anticancer | Osteosarcoma | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Human immunodeficiency virus | JR-FL luciferase reporter virus | | Luciferase reporter assay | Decrease (90 %) | Investigational | 26807966 |
| DrugRepV_6487 | KX2-391 | NA | Colon cancer | Pancreatic cancer | Prostate cancer | Breast cancer | Human immunodeficiency virus | HXB2 luciferase reporter virus | | Luciferase reporter assay | Decrease (80 %) | Investigational | 26807966 |
| DrugRepV_6488 | KX2-391 | NA | Colon cancer | Pancreatic cancer | Prostate cancer | Breast cancer | Human immunodeficiency virus | JR-FL luciferase reporter virus | | Luciferase reporter assay | Decrease (90 %) | Investigational | 26807966 |
| DrugRepV_6489 | Src inhibitor-1 | Anticancer | Pancreatic cancer | Breast cancer | Stomach cancer | Human immunodeficiency virus | HXB2 luciferase reporter virus | | Luciferase reporter assay | Decrease (60 %) | NA | 26807966 |
| DrugRepV_6490 | Src inhibitor-1 | Anticancer | Pancreatic cancer | Breast cancer | Stomach cancer | Human immunodeficiency virus | JR-FL luciferase reporter virus | | Luciferase reporter assay | Decrease (75 %) | NA | 26807966 |
| DrugRepV_6506 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Human immunodeficiency virus | HIV-1JR-FL env | | Luciferase reporter assay | Decrease (80 %) | Approved, Investigational | 15385252 |
| DrugRepV_6507 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Human immunodeficiency virus | HIV-1 VSV-G env | | Luciferase reporter assay | Decrease (60 %) | Approved, Investigational | 15385252 |
| DrugRepV_6508 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Human immunodeficiency virus | HIV-1 AML-V env | | Luciferase reporter assay | No significant effect (40 %) | Approved, Investigational | 15385252 |
| DrugRepV_6509 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Human immunodeficiency virus | HIV-1 VSV-G env | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 15385252 |
| DrugRepV_7007 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 28814523 |
| DrugRepV_7008 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28814523 |
| DrugRepV_7009 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28814523 |
| DrugRepV_7010 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 28814523 |
| DrugRepV_7011 | Nelfinavir Mesylate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | NA | 28814523 |
| DrugRepV_7012 | Lacidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 28814523 |
| DrugRepV_7013 | Butoconazole Nitrate | Genito Urinary System and Sex Hormones | Vulvovaginal candidiasis | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28814523 |
| DrugRepV_7014 | Sulconazole Nitrate | Dermatologicals | Fungal infections (Tinea cruris and Tinea corporis) | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | NA | 28814523 |
| DrugRepV_7015 | Mitotane | Antineoplastic and Immunomodulating Agents | Adrenocortical tumours | Cushing's syndrome | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28814523 |
| DrugRepV_7031 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (99 %) | Approved, Investigational | 28814523 |
| DrugRepV_7032 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (98 %) | Approved | 28814523 |
| DrugRepV_7033 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (96 %) | Approved | 28814523 |
| DrugRepV_7034 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_7035 | Nelfinavir Mesylate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (70 %) | NA | 28814523 |
| DrugRepV_7036 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (65 %) | Approved, Investigational | 28814523 |
| DrugRepV_7037 | Cilnidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (90 %) | Approved | 28814523 |
| DrugRepV_7038 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (95 %) | Approved | 28814523 |
| DrugRepV_7039 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (95 %) | Approved, Investigational | 28814523 |
| DrugRepV_7040 | Nelfinavir Mesylate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (100 %) | NA | 28814523 |
| DrugRepV_7041 | Manidipine | Cardiovascular agents | Hypertension | West Nile virus | WNV replicon | | Luciferase reporter assay | Decrease (55 %) | Approved, Investigational | 28814523 |
| DrugRepV_7042 | Cilnidipine | Cardiovascular agents | Hypertension | West Nile virus | WNV replicon | | Luciferase reporter assay | Decrease (90 %) | Approved | 28814523 |
| DrugRepV_7043 | Benidipine Hydrochloride | Cardiovascular agents | Hypertension | West Nile virus | WNV replicon | | Luciferase reporter assay | Decrease (90 %) | Approved | 28814523 |
| DrugRepV_7044 | Pimecrolimus | Dermatologicals | Atopic dermatitis | West Nile virus | WNV replicon | | Luciferase reporter assay | Decrease (88 %) | Approved, Investigational | 28814523 |
| DrugRepV_7045 | Nelfinavir Mesylate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | West Nile virus | WNV replicon | | Luciferase reporter assay | Decrease (72 %) | NA | 28814523 |